Episodes of vomiting are most likely to occur during the initial phases of treatment or following dose increases
Clinical trial data have generated significant interest in retatrutide because of its substantial weight-loss results, including Phase 3 findings showing average body weight reductions of more than 30% at the highest studied dose over 80 weeks
A strong nutrition plan may include lean protein, vegetables, fiber-rich carbohydrates, healthy fats and enough fluids
The science is early but compelling, and it challenges the simple narrative that tirzepatide causes headaches and nothing more
Acknowledgements We thank the School of Biomedical Sciences and CHIRI for financial support and excellent research facilities, respectively
Doctors get clear guidance on who should and shouldn't use it, and patients get a real understanding of the risks and benefits